 Home > Active Ingredient News > Blood System > J Clin Oncol: Ibrutinib treatment can significantly increase the risk of atrial fibrillation, bleeding and heart failure in CLL patients

J Clin Oncol: Ibrutinib treatment can significantly increase the risk of atrial fibrillation, bleeding and heart failure in CLL patients

 Last Update: 2021-09-11
 Source: Internet
 Author: User

Tags

water based cream

associated storage

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Ibrutinib can reduce the mortality of chronic lymphocytic leukemia (CLL)
.

But it also increases the risk of atrial fibrillation (AF, AF) and bleeding, causing people to worry about heart failure ( heart failure , HF) and central nervous system ischemia events

Heart failure

Using a linked administrative database, researchers such as Abdel-Qadir conducted a population-based cohort study on Ontario patients diagnosed with CLL from 2007 to 2019.
Patients treated with ibrutinib and unused with chemotherapy Patients who had been treated with ibrutinib were matched and analyzed
.

The findings were AF-related healthcare contacts, hospital- diagnosed bleeding, newly diagnosed HF, and hospitalizations for stroke and acute myocardial infarction (AMI)

Diagnosis of stroke myocardial infarction

Cumulative incidence of atrial fibrillation in the two groups for 1-3 years

A total of 778 CLL patients treated with ibrutinib and those who had not been exposed to ibrutinib were matched (n=1556)
.

The 3-year AF-related healthcare exposure rates of ibrutinib- treated patients and control patients were 22.

778 The 3-year AF-related health care exposure rate of ibrutinib- treated patients and control patients were 22.

Cumulative incidence of bleeding in the two groups for 1-3 years

Patients treated with ibrutinib are more likely to start anticoagulation therapy earlier
.

After adjusting for anticoagulation as a time-varying covariate, ibrutinib was still positively associated with bleeding (HR 2.

The 3-year HF risk of ibrutinib-treated patients and control patients were 7.

Cumulative incidence of heart failure in the two groups for 1-3 years

In summary, ibrutinib is associated with an increased risk of AF, bleeding, and HF in patients with chronic lymphocytic leukemia , but has nothing to do with the risk of AMI or stroke

Ibrutinib is associated with an increased risk of AF, bleeding, and HF in patients with chronic lymphocytic leukemia Ibrutinib is associated with an increased risk of AF, bleeding, and HF in patients with chronic lymphocytic leukemia

Original source:

Husam Abdel-Qadir, et al.

Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study In this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.